Oppenheimer analyst Suraj Kalia raised the firm’s price target on Artivion to $30 from $25 and keeps an Outperform rating on the shares following the Q2 results. The company continues to perform and beat and/or match expectations, and AMDS and NEXUS, assuming current timelines hold, could help propel growth into the high-teens range, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion Reports Second Quarter 2024 Financial Results
- Artivion Inc. (AORT) Q2 Earnings Cheat Sheet
- Lake Street highlights five ‘bargain bin’ small cap healthcare ideas for 2H
- Artivion price target raised to $30 from $28 at Lake Street
- Artivion Bolsters Endospan Partnership with Enhanced Financing Terms